De­nal­i's Hunter syn­drome ther­a­py gets pri­or­i­ty re­view; LENZ inks Cana­da deal

De­nali gets pri­or­i­ty re­view for rare dis­ease ther­a­py: The pro­gram, called tiv­i­de­no­fusp al­fa, is de­signed to treat Hunter syn­drome, a pro­tein mis­fold­ing dis­ease that be­gins …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.